- Home
- AVTX vs SABA Comparison
AVTX vs SABA Comparison
Compare AVTX & SABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$17.11
Company Overview
Basic Information| Metric | AVTX | SABA |
|---|---|---|
| Founded | 2011 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.3M | 240.1M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | AVTX | SABA |
|---|---|---|
| Price | $17.11 | $8.30 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $32.29 | N/A |
| AVG Volume (30 Days) | ★ 302.8K | 290.0K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.91% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $192,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.39 | $3.64 |
| 52 Week High | $20.72 | $4.42 |
Technical Indicators
Market Signals| Indicator | AVTX | SABA |
|---|---|---|
| Relative Strength Index (RSI) | 48.21 | 33.95 |
| Support Level | $15.49 | $8.29 |
| Resistance Level | $18.54 | $8.44 |
| Average True Range (ATR) | 1.17 | 0.09 |
| MACD | -0.28 | -0.01 |
| Stochastic Oscillator | 44.93 | 17.43 |
Price Performance
Historical Comparison AVTX
SABA
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About SABA Saba Capital Income & Opportunities Fund II Shares of Beneficial Interest
Saba Capital Income & Opportunities Fund II is a closed-end fund. The company seeks high current income, with a secondary goal of capital appreciation. The fund invests in fixed income markets across the globe.